Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient’s chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ya-Hui, Chen, Yi-Chun, Lin, Chi-Chen, Hsieh, Yao-Peng, Hsu, Chien-Sheng, Hsieh, Ming-Chia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306478/
https://www.ncbi.nlm.nih.gov/pubmed/32606957
http://dx.doi.org/10.2147/CMAR.S247876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306478/
https://www.ncbi.nlm.nih.gov/pubmed/32606957
http://dx.doi.org/10.2147/CMAR.S247876

Ejemplares similares